Meeting NewsPerspective

Off-the-shelf CAR T-cell therapy induces durable remissions in relapsed, refractory B-cell malignancies

February 21, 2020
ORLANDO — Off-the-shelf chimeric antigen receptor T-cell therapy induced durable remissions among patients with relapsed or refractory B-cell…
Meeting News

Acute GVHD less severe after haploidentical transplant with post-cyclophosphamide prophylaxis

February 21, 2020
ORLANDO — Acute graft-versus-host disease tended to be less severe among patients who underwent haploidentical transplantation with…
Meeting NewsPerspective

Sitagliptin reduces acute GVHD after peripheral blood stem cell transplantation

February 21, 2020
ORLANDO — The anti-diabetic medication sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative…
Meeting News

Autologous, allogeneic HSCT ‘highly efficacious’ for Waldenström macroglobulinemia

February 21, 2020
ORLANDO — Autologous and allogeneic hematopoietic stem cell transplantation both conferred encouraging survival outcomes among patients with…
Meeting News

Response to hypomethylating agents may not predict survival after HSCT for AML

February 20, 2020
ORLANDO — Patients with acute myeloid leukemia who failed to achieve complete remission with hypomethylating agent-based therapy still had…
Meeting News

Myeloablative conditioning before HSCT confers survival benefit in AML, myelodysplastic syndrome

February 20, 2020
ORLANDO — Myeloablative conditioning before hematopoietic stem cell transplantation conferred a long-term survival advantage compared with…
Meeting NewsPerspective

Outpatient treatment with lisocabtagene maraleucel feasible for certain patients with non-Hodgkin lymphoma

February 20, 2020
ORLANDO — Patients with relapsed or refractory large B-cell non-Hodgkin lymphoma can be successfully treated and monitored in the outpatient…
Meeting NewsPerspective

CPX-351 prolongs OS compared with 7 + 3 chemotherapy in AML with myelodysplasia-related changes

February 20, 2020
ORLANDO — CPX-351 extended OS compared with 7 + 3 chemotherapy among patients with acute myeloid leukemia and myelodysplasia-related changes…
Meeting NewsPerspective

HSCT after quizartinib or chemotherapy extends OS in AML subset

February 20, 2020
ORLANDO — Hematopoietic stem cell transplantation after treatment with quizartinib or salvage chemotherapy extended survival among patients…
Meeting NewsPerspective

Timing, patterns of relapse predict survival after HSCT for multiple myeloma

February 19, 2020
ORLANDO — Time to relapse appeared prognostic for survival among individuals with multiple myeloma who underwent CD34 positive-selected…